Performance of pre‐transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout

Piñero, Federico; Thompson, Marcos; Boin, Ilka de Fátima Ferreira; Chagas, Aline Lopes; Quiñonez, Emilio; Bermúdez, Carla; Vilatobá, Mario; Santos, Leonardo Soares dos; Anders, Margarita; Duque, Sergio Hoyos; Lima, Agnaldo Soares; Menéndez, J. Carlos; Padilla, Martín; Poníachik, Jaime; Zapata, Rodrigo; Maraschio, Martín; Menéndez, Ricardo Chong; Muñoz, Linda; Arufe, Diego; Figueroa, Rodrigo; Perales, Simone Reges; Maccali, Claudia; Sandoval, Rodrigo Vergara; McCormack, Lucas; Varón, Adriana; Marciano, Sebastián; Mattera, Juan; Carrilho, Flair José; Silva, Marcelo

doi:10.1111/liv.15223

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to radiographic or explant tumor burden, AFP is an important predictor of tumor-specific survival. Higher AFP levels have been consistently identified as a risk factor for waitlist dropout [49][50][51] and as a negative predictor of post-LT outcome. [48,[52][53][54] In the down-staging population in particular, AFP > 100 ng/mL has been identified as the threshold associated with a higher risk of HCC recurrence and death, with 3-year post-LT survival of 60% compared with > 80% among patients with HCC with AFP < 20 ng/mL at the time of LT. [26] In the MERITS-LT down-staging consortium, [30] pre-treatment AFP-L3 Z 10% (HR 3.7, p value 0.02) has been associated with increased dropout risk.…”

Section: Predictors Of Inferior Down-staging-related Outcomesmentioning

confidence: 99%

Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies

2023

View full text Add to dashboard Cite

Section: Predictors Of Inferior Down-staging-related Outcomesmentioning

confidence: 99%

Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies

2023

View full text Add to dashboard Cite

Benefit and harm of waiting time in liver transplantation for HCC

van der Meeren,

de Wilde,

Sprengers

et al. 2023

Hepatology

View full text Add to dashboard Cite

Liver transplantation is the most successful treatment for limited-stage HCC. The waiting time for liver transplantation (LT) can be a critical factor affecting the oncological prognosis and outcome of patients with HCC. Efficient strategies to optimize waiting time are essential to maximize the benefits of LT and to reduce the harm of delay in transplantation. The ever-increasing demand for donor livers emphasizes the need to improve the organization of the waiting list for transplantation and to optimize organ availability for patients with and without HCC. Current progress in innovations to expand the donor pool includes the implementation of living donor LT and the use of grafts from extended donors. By expanding selection criteria, an increased number of patients are eligible for transplantation, which necessitates criteria to prevent futile transplantations. Thus, the selection criteria for LT have evolved to include not only tumor characteristics but biomarkers as well. Enhancing our understanding of HCC tumor biology through the analysis of subtypes and molecular genetics holds significant promise in advancing the personalized approach for patients. In this review, the effect of waiting time duration on outcome in patients with HCC enlisted for LT is discussed.

show abstract

Performance of pre‐transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout

Abstract: Background & aim: Liver transplantation (LT) selection models for hepatocellular carcinoma (HCC) have not been proposed to predict waitlist dropout because of tumour

Cited by 2 publications

References 31 publications

Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies

Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies

Benefit and harm of waiting time in liver transplantation for HCC

Contact Info

Product

Resources

About